- Home
- DBRG vs DNTH Comparison
DBRG vs DNTH Comparison
Compare DBRG & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBRG
- DNTH
- Stock Information
- Founded
- DBRG 1991
- DNTH 2015
- Country
- DBRG United States
- DNTH United States
- Employees
- DBRG N/A
- DNTH N/A
- Industry
- DBRG Real Estate Investment Trusts
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- DBRG Real Estate
- DNTH Health Care
- Exchange
- DBRG Nasdaq
- DNTH Nasdaq
- Market Cap
- DBRG 1.8B
- DNTH 1.5B
- IPO Year
- DBRG 2009
- DNTH N/A
- Fundamental
- Price
- DBRG $11.79
- DNTH $38.88
- Analyst Decision
- DBRG Strong Buy
- DNTH Strong Buy
- Analyst Count
- DBRG 7
- DNTH 10
- Target Price
- DBRG $16.00
- DNTH $66.38
- AVG Volume (30 Days)
- DBRG 1.9M
- DNTH 989.4K
- Earning Date
- DBRG 10-31-2025
- DNTH 11-06-2025
- Dividend Yield
- DBRG 0.34%
- DNTH N/A
- EPS Growth
- DBRG N/A
- DNTH N/A
- EPS
- DBRG N/A
- DNTH N/A
- Revenue
- DBRG $173,540,000.00
- DNTH $4,854,000.00
- Revenue This Year
- DBRG N/A
- DNTH N/A
- Revenue Next Year
- DBRG $77.07
- DNTH N/A
- P/E Ratio
- DBRG N/A
- DNTH N/A
- Revenue Growth
- DBRG N/A
- DNTH 17.87
- 52 Week Low
- DBRG $6.41
- DNTH $13.37
- 52 Week High
- DBRG $17.33
- DNTH $39.70
- Technical
- Relative Strength Index (RSI)
- DBRG 57.87
- DNTH 84.91
- Support Level
- DBRG $11.13
- DNTH $36.00
- Resistance Level
- DBRG $12.58
- DNTH $24.81
- Average True Range (ATR)
- DBRG 0.37
- DNTH 2.76
- MACD
- DBRG 0.04
- DNTH 1.05
- Stochastic Oscillator
- DBRG 48.04
- DNTH 95.37
About DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.